Related Experiment Video
Updated: Jun 22, 2026
11:16
Non-invasive Imaging of the Innate Immune Response in a Zebrafish Larval Model of Streptococcus iniae Infection
Published on: April 21, 2015
11.0K
Research Advances on Tilapia Streptococcosis
Ze Zhang1,2,3
1College of Life Sciences, Beijing Normal University, Beijing 100875, China.
Pathogens (Basel, Switzerland)
|June 2, 2021
Summary
Streptococcus agalactiae (GBS) causes significant losses in tilapia aquaculture. This review details its virulence factors and explores promising vaccine antigens for disease prevention.
Area of Science:
- Aquatic animal health
- Bacterial pathogenesis
- Vaccine development
Background:
- Streptococcus agalactiae, or group B Streptococcus (GBS), is a major pathogen affecting tilapia in commercial aquaculture.
- GBS infection, known as streptococcosis, leads to substantial economic losses and clinical signs such as abnormal behavior, exophthalmos, and meningitis.
Purpose of the Study:
- To review the etiology, pathology, and virulence factors of Streptococcus agalactiae in tilapia.
- To summarize current research on vaccine prospects against GBS in aquaculture.
Main Methods:
- Comprehensive literature review of studies on Streptococcus agalactiae.
- Analysis of identified virulence factors and potential vaccine antigens.
Main Results:
- Key virulence factors identified include capsular polysaccharide (CPS), hemolysin, CAMP factor, hyaluronidase (HAase), superoxide dismutase (SOD), and serine-threonine protein kinase (STPK).
- Effective vaccine antigens reported include GapA, Sip, OCT, PGK, FbsA, and EF-Tu.
Conclusions:
- Understanding GBS virulence factors is crucial for developing effective prevention and treatment strategies.
- Further research into specific antigens like GapA, Sip, and others holds promise for tilapia streptococcosis vaccines.
